THROMBOLYSIS OUTCOMES IN ACUTE ISCHEMIC STROKE PATIENTS WITH PRIOR STROKE AND DIABETES MELLITUS

Gaetano Santulli, New York: Mishra et al. examined the influence of diabetes mellitus and prior stroke on the outcomes of patients who received thrombolysis vs nonthrombolyzed controls. They found no interaction on outcome between diabetes and prior stroke with thrombolysis treatment. These results conflict with the European Medicines Evaluation Agency’s justification for restricting the use of IV alteplase. As Dr. Demaerschalk mentioned in the accompanying editorial, recent studies have suggested that thrombolysis can be safely used in several groups of patients who do not qualify for treatment due to strict application of exclusion criteria. In addition, most of the commonly cited thrombotic exclusion criteria are just consensus-based, not evidence-based. It is time to reevaluate the criteria for thrombolysis, adopting a clinical score to stratify the risk, similar to those used in acute coronary syndrome. A good risk assessment tool will be able to identify a gradient of mortality risk by using variables that capture the majority of prognostic information to better evaluate the risk/benefit ratio for each patient.

Copyright © 2012 by AAN Enterprises, Inc.


A RANDOMIZED TRIAL OF HIGH-DOSE VITAMIN D2 IN RELAPSING-REMITTING MULTIPLE SCLEROSIS

Helmut H. Leitner, Vienna: Stein et al. compared high- vs low-dose vitamin D2 treatment in MS without benefit in the high-dose treatment group. Sunlight exposure and reduced vitamin D3 levels independently contribute to MS risk. The effect of sunlight exposure is supported by decreased signs of actinic skin damage found in MS patients compared to controls. It is difficult to determine which of these 2 environmental factors is of primary importance as higher levels of sunlight exposure will enhance vitamin D levels.

The incidence of vitamin D–related rickets disease decreased in the United States and Europe during the last century following the discovery that vitamin D possessed antirachitic properties, whereas the incidence of MS seemed to increase in the same population. In the United States, most of the patients with rickets are African American, whereas the majority of patients with MS are of European ancestry. It seems improbable that the same environmental factor should be centrally involved in the etiology of both diseases, which differ clinically and occur in different populations living in the same geographic area.

These findings together with those of Stein et al. do not provide a reason for vitamin D supplementa-
tion in MS aside from correcting a proven vitamin D deficiency. Other factors associated with increased sunlight exposure may more effectively prevent MS.

L. Grimaldi, Cefalù, Italy; F. Barkhof, Amsterdam; M. Beelke, Gauting-Unterbrunn, Germany; J. Burton, Calgary, Canada; T. Holmøy, Oslo; R. Hupperts, Sittard, the Netherlands; J. Killestein, Amsterdam; P. Rieckmann, Wurzburg, Germany; M. Schluep, Lausanne, Switzerland; J. Smolders, Amsterdam; on behalf of the SOLAR study group:

The conclusion of Stein et al.1 that high-dose ineffective vs low-dose vitamin D2 supplementation in relapsing-remitting MS (RRMS) is not supported by data enabling level 1 evidence.

Randomization to interferon-β, glatiramer acetate, or no treatment results in very small treatment groups. Such MRI-based randomized placebo-controlled trials would need at least 85 patients per arm to reach statistical significance, assuming 50% treatment difference4 and, since vitamin D effects may appear after 12–24 weeks, an MRI follow-up period of at least 9—not 6—months.

In figure 2, only 4/11 subjects in the higher dose group exhibited 25(OH)D levels within the 130–175 nmol/L target range.1 Since dosages must have been adjusted continuously throughout the trial, likely fluctuations in serum 25(OH)D prevent firm conclusions.5

During the study, MKTVIF75HV (vitamin D2) was replaced by vitamin D3. As vitamin D2 and D3 are not equivalent,5 these results cannot be extended to all “vitamin D” subtypes.

To address these issues, an appropriately powered, randomized, double-blind, placebo-controlled, phase II study (SOLAR) of high-dose vitamin D3 (vigantol oil, 14,000 IU/d) add-on to interferon β-1a, 44 μg subcutaneously 3 times weekly (Rebif), for 96 weeks in 348 RRMS patients, is currently under way.6

The SOLAR study group also includes Reinhold Vieth (SC member), Lizette Ghazi (SC member), Klemens Anguwurm, Simone Cursiefen, Ana Martins de Silva, Jan-Markus Dirr, Irina Elovaara, Juha-Pekka Eräinlinna, Markus Färkkilä, Masoud Falah, Jette Frederiksen, Steven Frequin, Claudio Gobbi, Bernd Griewling, Katrin Gross-Paju, Elisabeth Gulowesen Celius, Christina Kading, Claudia Kaiser, Jolanta Kahlina, Christian Kamm, Margitta Kampman, Keijo Koivisto, Samuel Komoly, Christian Lampl, Dalia Mickeviciene, Kjell-Morton Myhr, Lina Malciene, Michael Linnebank, Martin Marziniak, Said Masri, Stefanie Müller, Rui Pedrosa, Dieter Pöhla, Nils Richter, Thorsten Rosenkranz, Cailla Rozsa, Ma José Sá, Vasco Salgado, Johnny Samijn, Evert Sanders, Taneti Sarasoja, Okke Sinnige, Bjarne Siertsen, Merja Soile-Hanninen, Martin Stangel, Egon Stenager, Olivier Stoch, Florian Stögbauer, Toomas Toomsoo, Sabine Urbanits, László Vécsei, Freek Verheul, and Uwe K. Zettl.

Copyright © 2012 by AAN Enterprises, Inc.


Author disclosures are available upon request (journal@neurology.org).
A Randomized Trial of High-Dose Vitamin D2 in Relapsing-remitting Multiple Sclerosis
Neurology 2012;78;840-841
DOI 10.1212/01.wnl.0000413180.13413.ce

This information is current as of March 12, 2012